Zydus Lifesciences Limited announced its audited financial results for the quarter and year ended 31 March 2025.
Total revenue from operations grew by 18% YoY to ₹65,279 million.
EBITDA stood at ₹21,255 million with a margin of 32.6%, up 310 bps YoY.
Net profit (excluding exceptional items) was ₹13,905 million, an increase of 18% YoY.
The company's India formulations business outperformed the market, growing 11% YoY, driven by key brands and new products; chronic portfolio share increased to 43%.
Consumer Wellness business delivered double-digit growth, supported by volume growth and the acquisition of Naturell (India) Pvt. Ltd.
US formulations business experienced strong growth, driven by volume expansion and new product launches; 17 new products launched in FY25.
International markets formulations business also grew strongly due to demand across geographies.
R&D expenses for the quarter were ₹4,799 million, representing 7.4% of revenues.
Capex (organic) for the quarter amounted to ₹3,202 million.
Net cash stood at ₹48,836 million as of 31 March 2025, compared to ₹8,561 million the previous year.
The Ambernath API manufacturing facility received an Establishment Inspection Report (EIR) with No Action Indicated (NAI) status from the USFDA.
Zydus forayed into the MedTech space by acquiring a majority stake in Amplitude Surgical SA, France.
Zydus Lifesciences holds the 2nd position in the ESG Rating by S&P Global for 2024 (Indian peers).